Paul G Richardson is affiliated with the Jerome Lipper Multiple Myeloma Center.[1]He specializes in clinical research.[1]
Dr. Paul Richardson is the RJ Corman Professor of Medicine at Harvard Medical School, Clinical Program Leader, and Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, Massachusetts.[2]His primary research interest is in novel therapies, and he has been a leader in the clinical development of bortezomib, lenalidomide and pomalidomide.[2]He is the prior Chairman of the MMRC and serves on the Steering Committees and he now chairs the newly formed Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology.[3]He was a co-recipient of the Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway.[4]He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research.[4]Dr. Richardson has published more than 340 articles and 260 reviews, chapeters and editorials in peer-reviewed journals such as the New England Journal of Medicine, Blood, the Journal of Clinical Oncology, Leukemia, and many more.[4]
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
Jerome Lipper Multiple Myeloma Center
3
585
148
Dr. Paul Richardson of the Dana Farber Cancer Institute provides the myeloma patient community with a great synopsis of all relevant announcements shared at the virtual American Society of Clinical Oncology meeting held May 29-31, 2020. Dr. Paul Richardson is RJ Corman Professor of Medicine at Harvard Medical School and the Attending Physician in the Division of Hematologic Oncology and the Multiple Myeloma and Bone Marrow Transplant Service at the Dana-Farber Cancer Institute.[10]
05/19/2020
The FDA has seen fit to approve Bristol-Myers Squibb's Empliciti intravenous injection in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma, it has emerged. The decision came off the back of Phase 2 data which showed that the therapy doubled progression-free survival and overall response rate compared to pomalidomide and dexamethasone alone in relapsed or refractory multiple myeloma. "Despite remarkable recent innovations with novel therapies for the treatment of multiple myeloma, many patients still face poor outcomes, and particularly in the relapsed and relapsed, refractory setting," said Dr Paul Richardson, Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. Today's approval reinforces the importance of Immuno-Oncology in blood cancers and expands the role of Empliciti to address the needs of relapsed or refractory multiple myeloma patients."[89]
11/07/2018
In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. The results of the trial - a combined phase 1 and 2 study - strongly support testing of the drug in a larger group of patients in both phase 2 and 3 trials, the authors say. "The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors and potent immuno-modulatory agents," said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana-Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School. The new study involved 72 patients, all of whom had received at least two prior lines of therapy and whose disease had relapsed and no longer responded to treatment.[567]
08/27/2015